ArticleCell biochemistry and biophysics2026
A Three-Dimensional Hyaluronic Acid-Based Scaffold Model for Electroporation-Enhanced Resveratrol Therapy in Triple-Negative Breast Cancer.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive malignancy defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These molecular characteristics render targeted therapies less effective and contribute to poor clinical outcomes. Towards this, we studied the electroporation-mediated delivery of resveratrol, a polyphenolic compound with pleiotropic anticancer activities, on MDA-MB-231, human TNBC cell line. Both conventional two dimensional (2D) monolayer cell culture and three-dimensional (3D) hyaluronic acid HA-EAbuK-IKVAV scaffold-based cell cultures were used. Two electroporation (EP) protocols (EP1: 8 pulses, 800 V/cm, 100 µs at 1 Hz; EP2: 8 pulses, 1000 V/cm, 100 µs at 1 Hz) were evaluated for their effects on cytotoxicity and reactive oxygen species (ROS) generation. In 3D, the combined treatment similarly reduced viability to 20% (EP1 + Resv) and 17% (EP2 + Resv), whereas in 2D, the viability reduction is 24% and 18%, respectively. Mechanistically, ROS levels increased substantially with the combination treatment: in 2D, ROS rose to 3 times (EP1 + Resv) and around 3.5 times (EP2 + Resv) the control, while in 3D, ROS increased to 2.4 times (EP1 + Resv) and 2.9 times (EP2 + Resv). Moreover, the combined treatment of electroporation and resveratrol administration on 3D HA-EAbuK-IKVAV-cultured cells decreased the expression of cell cycle regulatory protein Cdk2 and proliferation marker Ki67. These findings highlight the importance of 3D microenvironmental cues in modulating TNBC responsiveness to resveratrol and underscore the potential of combining electroporation with natural compounds as a rational therapeutic strategy for this challenging subtype of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.